Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
| ▸ | LIPE | Q05469 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45699 | 1.00 | NR1H2 (0.41) | NR1H2USP30GPR119LIPERORC | |
| SCHEMBL7397405 | 0.77 | GPR119 (0.44) | NR1H2GPR119 | |
| SCHEMBL4121106 | 0.76 | GPR119 (0.43) | NR1H2USP30GPR119KDM4E | |
| SCHEMBL15908907 | 0.74 | NR1H2 (0.42) | NR1H2USP30GPR119LIPEJAK1 | |
| SCHEMBL15908906 | 0.74 | NR1H2 (0.42) | NR1H2USP30GPR119LIPEJAK1 | |
| SCHEMBL15909048 | 0.73 | NR1H2 (0.51) | NR1H2USP30GPR119LIPERORC | |
| SCHEMBL15909049 | 0.73 | NR1H2 (0.51) | NR1H2USP30GPR119LIPERORC | |
| SCHEMBL15634408 | 0.70 | NR1H2 (0.51) | NR1H2USP30GPR119LIPERORC | |
| SCHEMBL22871669 | 0.70 | GPR119 (0.48) | USP30GPR119 | |
| SCHEMBL950789 | 0.70 | GPR119 (0.53) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796470-B2 | Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ORAI1, CACNA1E, RYR1 | NR1H2 1912/4885USP30 4652/4885GPR119 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.